Get the Daily Brief
Latest Biotech News
AstraZeneca Prunes Cell Therapy Portfolio, Ditches Lead TCR Candidate and CAR-Ts
AstraZeneca discontinued its lead T-cell receptor therapy NT-125 and two armored CAR-T candidates, AZD5851 and AZD6422, citing strategic portfolio prioritization. Despite acquiring Neogene...
Sarepta Resumes Shipping Elevidys Gene Therapy to Ambulatory DMD Patients
Following an FDA review, Sarepta Therapeutics resumed shipments of Elevidys® gene therapy to ambulant Duchenne muscular dystrophy (DMD) patients after a brief pause triggered by safety concerns....
Celcuity Surges on Positive Phase III Breast Cancer Gedatolisib Trial
Minneapolis-based biotech Celcuity announced positive top-line Phase III trial results for gedatolisib in combination therapies for hormone receptor-positive, HER2-negative advanced breast cancer....
GSK and Jiangsu Hengrui Seal $12B Multi-Drug Deal Targeting COPD and More
GlaxoSmithKline (GSK) inked a $500 million upfront agreement with China’s Jiangsu Hengrui Pharmaceuticals for exclusive rights to HRS-9821, a potential best-in-class PDE3/4 inhibitor for chronic...
National Institutes of Health Develops AI Agent to Enhance Gene Set Analysis Accuracy
NIH researchers have introduced GeneAgent, an AI-powered large language model system that improves gene-set function prediction accuracy by autonomously verifying outputs against expert-curated...
New Technique Enables Single-Cell Mapping of Transcription Factor Binding
Scientists at the University of Cologne have developed DynaTag, a novel method that maps transcription factor (TF) binding sites at single-cell resolution and in low-input samples. Utilizing...
Private Equity Targets Vaccine Maker Bavarian Nordic in $3 Billion Buyout
Bavarian Nordic, a leading vaccine manufacturer known for its mpox vaccine supply in the U.S. and EU, is poised for acquisition by a consortium led by Nordic Capital and Permira in a deal valued...
Sarepta’s Duchenne Therapy Resumes After FDA Safety Review
Sarepta Therapeutics has received FDA authorization to resume shipments of its gene therapy Elevidys to ambulatory patients with Duchenne muscular dystrophy following a thorough investigation into...
Celcuity’s Breast Cancer Drug Tops Phase III — Shares Triple
Minneapolis-based Celcuity reported positive top-line results from its Phase III Viktoria-1 trial evaluating the breast cancer drug gedatolisib. The drug, tested in hormone receptor-positive,...
GSK and Hengrui Pharma Strike $12.5 Billion Deal for COPD Pipeline
GlaxoSmithKline entered a multi-billion-dollar licensing agreement with Jiangsu Hengrui Pharmaceuticals granting GSK rights to a portfolio of 12 drugs, including a promising phase I...
Adaptimmune Sells Cell Therapy Assets Amid Financial Strain
Adaptimmune, facing significant financial challenges, is selling its three cell therapy assets, including the FDA-approved sarcoma drug Tecelra, to US WorldMeds for an upfront payment of $55...
AI Enhances Gene Set Analysis Accuracy Through Database Verification
Researchers at the NIH have developed GeneAgent, an artificial intelligence agent based on large language models that improves the accuracy of gene set analysis by autonomously verifying its...
New DynaTag Method Maps Transcription Factors at Single-Cell Level
Scientists at the University of Cologne introduced DynaTag, a novel technique enabling high-resolution mapping of transcription factor binding sites even in single cells and low-input samples by...
Antimatter Qubits Created, Paving Way for Quantum Computing Advances
Physicists have succeeded in creating the first quantum bit (qubit) using antimatter—specifically a single trapped antiproton—achieving a nearly one-minute spin coherence time. Published in...
Mass Ivermectin Administration Cuts Malaria Transmission in Kenya
A cluster-randomized trial conducted in Kwale, Kenya tested monthly ivermectin administration in children over a three-month period to evaluate its impact on malaria transmission. The study...
Sanofi Leverages AI to Guide Drug Development Decisions
Sanofi’s CEO Paul Hudson disclosed that the company integrates artificial intelligence into its drug development pipeline decision-making processes. AI tools provide dispassionate recommendations...
New Arab Human Pangenome Assembled Using Long-Read Sequencing
A landmark study led by Mohammed Bin Rashid University assembled the first high-quality pangenome reference for Arab populations using PacBio’s HiFi long-read sequencing technology. Analyzing...
FDA Clears Sarepta Duchenne Therapy After Investigation
The FDA has resumed clearance for Sarepta Therapeutics' Elevidys gene therapy targeting ambulatory patients with Duchenne muscular dystrophy after a thorough safety review. This follows a...
Celcuity’s Breast Cancer Therapy Achieves Late-Stage Milestones
Celcuity reported positive phase III results for its breast cancer drug gedatolisib, significantly reducing progression risk in hormone receptor-positive, HER2-negative advanced tumors that were...
Adaptimmune Sells Cell Therapy Assets in Turnaround Effort
Cell therapy developer Adaptimmune announced the sale of its sarcoma therapy Tecelra and two late-stage assets to US WorldMeds for an upfront payment of $55 million, with potential $30 million in...